73 related articles for article (PubMed ID: 24395441)
1. Protective effect of the Y220C mutant p53 against steatosis: good news?
Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
[TBL] [Abstract][Full Text] [Related]
2. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
[TBL] [Abstract][Full Text] [Related]
3. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver.
Moya M; Benet M; Guzmán C; Tolosa L; García-Monzón C; Pareja E; Castell JV; Jover R
PLoS One; 2012; 7(1):e30014. PubMed ID: 22238690
[TBL] [Abstract][Full Text] [Related]
4. TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation.
Niture S; Gyamfi MA; Lin M; Chimeh U; Dong X; Zheng W; Moore J; Kumar D
Cell Death Dis; 2020 Mar; 11(3):178. PubMed ID: 32152268
[TBL] [Abstract][Full Text] [Related]
5. To die or not to die: death signaling in nonalcoholic fatty liver disease.
Akazawa Y; Nakao K
J Gastroenterol; 2018 Aug; 53(8):893-906. PubMed ID: 29574534
[TBL] [Abstract][Full Text] [Related]
6. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis.
Rafiei H; Yeung M; Kowalski S; Krystal G; Elisia I
Front Pharmacol; 2023; 14():1234300. PubMed ID: 37927606
[No Abstract] [Full Text] [Related]
8. Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis.
Prokesch A; Graef FA; Madl T; Kahlhofer J; Heidenreich S; Schumann A; Moyschewitz E; Pristoynik P; Blaschitz A; Knauer M; Muenzner M; Bogner-Strauss JG; Dohr G; Schulz TJ; Schupp M
FASEB J; 2017 Feb; 31(2):732-742. PubMed ID: 27811061
[TBL] [Abstract][Full Text] [Related]
9. A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease.
Lasli S; Kim HJ; Lee K; Suurmond CE; Goudie M; Bandaru P; Sun W; Zhang S; Zhang N; Ahadian S; Dokmeci MR; Lee J; Khademhosseini A
Adv Biosyst; 2019 Aug; 3(8):e1900104. PubMed ID: 32648699
[TBL] [Abstract][Full Text] [Related]
10. Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis.
Aoudjehane L; Gautheron J; Le Goff W; Goumard C; Gilaizeau J; Nget CS; Savier E; Atif M; Lesnik P; Morichon R; Chrétien Y; Calmus Y; Scatton O; Housset C; Conti F
Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32094147
[TBL] [Abstract][Full Text] [Related]
11. p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.
Krstic J; Galhuber M; Schulz TJ; Schupp M; Prokesch A
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558460
[TBL] [Abstract][Full Text] [Related]
12. AI-powered discovery of a novel p53-Y220C reactivator.
Zhou S; Chai D; Wang X; Neeli P; Yu X; Davtyan A; Young K; Li Y
Front Oncol; 2023; 13():1229696. PubMed ID: 37593097
[TBL] [Abstract][Full Text] [Related]
13. Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.
Han ISM; Thayer KM
ACS Omega; 2024 May; 9(18):19837-19847. PubMed ID: 38737036
[TBL] [Abstract][Full Text] [Related]
14. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.
Wilcken R; Liu X; Zimmermann MO; Rutherford TJ; Fersht AR; Joerger AC; Boeckler FM
J Am Chem Soc; 2012 Apr; 134(15):6810-8. PubMed ID: 22439615
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C.
Stephenson Clarke JR; Douglas LR; Duriez PJ; Balourdas DI; Joerger AC; Khadiullina R; Bulatov E; Baud MGJ
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1169-1180. PubMed ID: 36407959
[TBL] [Abstract][Full Text] [Related]
16. Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines.
Karaca M; Fritsche K; Lichtenstein D; Vural Ö; Kreuzer K; Alarcan J; Braeuning A; Marx-Stoelting P; Tralau T
STAR Protoc; 2023 Sep; 4(3):102500. PubMed ID: 37616165
[TBL] [Abstract][Full Text] [Related]
17. Extracellular and intracellular functions of coiled-coil domain containing 3.
Omari S; Lee H; Wang J; Zeng SX; Lu H
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37263799
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced cytotoxicity and cellular oxidative stress: implications for acute and chronic care of obese cancer patients.
AlGhamdi S; Leoncikas V; Plant KE; Plant NJ
Toxicol Res (Camb); 2015 Nov; 4(6):1479-1487. PubMed ID: 26744621
[TBL] [Abstract][Full Text] [Related]
19. Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C.
Stahlecker J; Klett T; Schwer M; Jaag S; Dammann M; Ernst LN; Braun MB; Zimmermann MO; Kramer M; Lämmerhofer M; Stehle T; Coles M; Boeckler FM
RSC Med Chem; 2022 Dec; 13(12):1575-1586. PubMed ID: 36561072
[TBL] [Abstract][Full Text] [Related]
20. TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma.
van Kempen PM; Verdam FJ; de Poel E; Braunius WW; de Weger RA; van Es RJ; Grolman W; Willems SM
Pathobiology; 2015; 82(1):21-27. PubMed ID: 25765855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
